Occlutech, a leading provider of minimally invasive structural heart devices, today announced the appointment of Thomas J. Bogenschütz as Chairman of its Board of Directors, effective immediately.
Mr. Bogenschütz brings over 30 years of experience in the medical technology industry, with a strong track record in building companies, leading international operations, and advancing cardiovascular innovations.
He is currently CEO of MEDIRA GmbH in Germany and co-founder and board member of MEDIRA AG in Switzerland. His prior leadership roles include Senior Vice President at CryoLife Inc., a NYSE-listed MedTech company, and CEO of New Valve Technology (NVT), which was acquired in 2020.
He also served as Managing Director of JOTEC GmbH, where he led the company through international expansion and its eventual acquisition. Beyond his executive roles, he has held several board positions including at Valtronic AG (Switzerland) and ENDOSPAN Ltd. (Israel), and currently serves as Chairman of Medical Valley Hechingen association, a key medtech network in Southern Germany.
“Occlutech has earned a solid reputation in the structural heart field, with a clear commitment to advancing meaningful solutions for patients,” said Thomas J. Bogenschütz. “I’m honoured to join as Chairman and look forward to working with the leadership team and Board to support the company’s continued growth and global expansion.”
“Thomas brings deep industry insight, international business acumen, and a strong strategic mindset,” said Tor Peters, CEO of Occlutech. “His appointment strengthens our governance and positions us well for the next stage of our growth.”
Mr. Bogenschütz holds a degree in Industrial Engineering from the University of Applied Sciences in Esslingen/Stuttgart.
– Ends –
About Occlutech
Occlutech is a leading specialist provider of minimally invasive structural heart devices, with a mission to improve the quality of life for people with heart conditions. The vision is to become a leading global specialist in cardiac devices, addressing congenital heart defects, stroke prevention and heart failure. Since 2003, the company has developed, manufactured, and commercialized occluders and interatrial shunt products. Occlutech has a broad and proven portfolio, based on proprietary technology, and over 200 patents with over 200,000 products sold. The company markets and sells its products in over 70 countries. The company has around 300 employees and is a public limited liability company registered in Switzerland. For more information, connect with Occlutech on LinkedIn or visit: www.occlutech.com
For more information contact:
Rebecca Fancini
Occlutech Public Relations
+44 (0) 7594 649094
rebecca.fancini@occlutech.com
Attachments
